G V Scagliotti1, I Bondarenko2, F Blackhall3, F Barlesi4, T-C Hsia5, J Jassem6, J Milanowski7, S Popat8, J M Sanchez-Torres9, S Novello10, R J Benner11, S Green11, K Molpus11, J-C Soria12, F A Shepherd13. 1. Department of Oncology, University of Turin, Orbassano, Turin, Italy giorgio.scagliotti@unito.it. 2. Department of Oncology, Dnepropetrovsk Medical Academy, City Multiple-Discipline Clinical Hospital #4, Dnepropetrovsk, Ukraine. 3. Manchester Cancer Research Centre Lung Group, Manchester University and Christie Hospital NHS Foundation Trust, Manchester, UK. 4. Department of Multidisciplinary Oncology and Therapeutic Innovations, Aix Marseille University-Assistance Publique Hôpitaux de Marseille, Marseille, France. 5. Department of Internal Medicine, China Medical University Hospital and China Medical University, Taichung, Taiwan. 6. Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk. 7. Department of Pneumology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland. 8. Lung Unit, Royal Marsden Hospital, London, UK. 9. Department of Medical Oncology, Hospital de la Princesa, Madrid, Spain. 10. Department of Oncology, University of Turin, Orbassano, Turin, Italy. 11. Department of Pfizer Oncology, Pfizer, Inc., Groton, USA. 12. Department of Clinical and Biological Sciences, Institut de Cancérologie Gustave Roussy and INSERM Unit 981, Villejuif, France. 13. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Ontario, Canada.
Abstract
BACKGROUND: Figitumumab (CP-751,871) is a fully human IgG2 monoclonal antibody that inhibits the insulin-like growth factor 1 receptor. This multicenter, randomized, phase III study investigated the efficacy of figitumumab plus erlotinib compared with erlotinib alone in patients with pretreated, nonsmall-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients (stage IIIB/IV or recurrent disease with nonadenocarcinoma histology) who had previously received at least one platinum-based regimen were randomized to receive open-label figitumumab (20 mg/kg) plus erlotinib 150 mg/day or erlotinib alone every 3 weeks. The primary end point was overall survival (OS). RESULTS: Of 583 patients randomized, 579 received treatment. The study was closed early by an independent data safety monitoring committee due to results crossing the prespecified futility boundary. At the final analysis, median OS was 5.7 months for figitumumab plus erlotinib and 6.2 months for erlotinib alone [hazard ratio (HR) 1.09; 95% confidence interval (CI) 0.91-1.31; P = 0.35]. Median progression-free survival was 2.1 months for figitumumab plus erlotinib and 2.6 months for erlotinib alone (HR 1.08; 95% CI 0.90-1.29; P = 0.43). Treatment-related nonfatal serious adverse events occurred in 18% and 5% of patients in the figitumumab arm or erlotinib alone arm, respectively. There were nine treatment-related deaths (three related to both drugs, four related to erlotinib alone and two related to figitumumab). CONCLUSIONS: The addition of figitumumab to erlotinib did not improve OS in patients with advanced, pretreated, nonadenocarcinoma NSCLC. Clinical development of figitumumab has been discontinued. CLINICAL TRIAL ID: NCT00673049.
BACKGROUND: Figitumumab (CP-751,871) is a fully human IgG2 monoclonal antibody that inhibits the insulin-like growth factor 1 receptor. This multicenter, randomized, phase III study investigated the efficacy of figitumumab plus erlotinib compared with erlotinib alone in patients with pretreated, nonsmall-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients (stage IIIB/IV or recurrent disease with nonadenocarcinoma histology) who had previously received at least one platinum-based regimen were randomized to receive open-label figitumumab (20 mg/kg) plus erlotinib 150 mg/day or erlotinib alone every 3 weeks. The primary end point was overall survival (OS). RESULTS: Of 583 patients randomized, 579 received treatment. The study was closed early by an independent data safety monitoring committee due to results crossing the prespecified futility boundary. At the final analysis, median OS was 5.7 months for figitumumab plus erlotinib and 6.2 months for erlotinib alone [hazard ratio (HR) 1.09; 95% confidence interval (CI) 0.91-1.31; P = 0.35]. Median progression-free survival was 2.1 months for figitumumab plus erlotinib and 2.6 months for erlotinib alone (HR 1.08; 95% CI 0.90-1.29; P = 0.43). Treatment-related nonfatal serious adverse events occurred in 18% and 5% of patients in the figitumumab arm or erlotinib alone arm, respectively. There were nine treatment-related deaths (three related to both drugs, four related to erlotinib alone and two related to figitumumab). CONCLUSIONS: The addition of figitumumab to erlotinib did not improve OS in patients with advanced, pretreated, nonadenocarcinoma NSCLC. Clinical development of figitumumab has been discontinued. CLINICAL TRIAL ID: NCT00673049.
Authors: David E Gerber; David A Boothman; Farjana J Fattah; Ying Dong; Hong Zhu; Rachel A Skelton; Laurin L Priddy; Peggy Vo; Jonathan E Dowell; Venetia Sarode; Richard Leff; Claudia Meek; Yang Xie; Joan H Schiller Journal: Lung Cancer Date: 2015-10-09 Impact factor: 5.705
Authors: Natasha B Leighl; Naiyer A Rizvi; Lopes Gilberto de Lima; Wichit Arpornwirat; Charles M Rudin; Alberto A Chiappori; Myung-Ju Ahn; Laura Q M Chow; Lyudmila Bazhenova; Arunee Dechaphunkul; Patrapim Sunpaweravong; Keith Eaton; Jihong Chen; Sonja Medley; Srinivasu Poondru; Margaret Singh; Joyce Steinberg; Rosalyn A Juergens; Shirish M Gadgeel Journal: Clin Lung Cancer Date: 2016-08-08 Impact factor: 4.785
Authors: Laura W Bowers; Emily L Rossi; Ciara H O'Flanagan; Linda A deGraffenried; Stephen D Hursting Journal: Front Endocrinol (Lausanne) Date: 2015-05-15 Impact factor: 5.555